Researchers from VIB and VUB now provide an interactive tool, based on a single-cell RNA-sequencing (scRNA-seq) atlas of the ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does ...

An elderly Oklahoma woman stricken with Parkinson’s Disease lost $20,000 in a cryptocurrency ploy that was crafted as a scam ...

Dr Braunstein, how would her cytogenetics and [disease] stage impact these treatment decisions ... This looked at patients ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.